A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

Guardant Health, Inc. ( NASDAQ: GH) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET AmirAli Talasaz - Co-CEO & Director Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman Michael Bell - Chief ...

Van Der Beek is opening up about his colon cancer to increase awareness of the importance of early detection, especially as ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Wednesday reported a loss of $99.9 million in its second quarter. The Palo Alto, California-based company said it had a ...